Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/8/2025 | $20.00 | Buy | Lake Street |
| 1/7/2025 | $15.00 | Buy | TD Cowen |
| 1/7/2025 | $9.00 | Overweight | Cantor Fitzgerald |
| 1/7/2025 | $22.00 | Overweight | Barclays |
MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the first patients have been enrolled and successfully treated in the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial for patients with severe calcific aortic stenosis (the "PARADIGM Trial"). The procedures were performed by Prof. Dr. Ole De Backer at, The Heart Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. "We a
MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that one-year clinical outcomes with the DurAVR® Transcatheter Heart Valve (THV) will be presented by Rishi Puri MD PhD, at TCT® 2025 – The 37th Annual Transcatheter Cardiovascular Therapeutics® Conference, taking place in San Francisco, California, October 25-28, 2025. An oral presentation is scheduled for Monday, October 27 (2:27pm GMT-7) in the Innovation Theater, Ha
MINNEAPOLIS and BRISBANE, Australia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced today it has received regulatory clearance from the Danish Medicines Agency to initiate the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial in patients with severe calcific aortic stenosis (the "PARADIGM Trial"). Patient recruitment at Danish centers is expected to begin in 4Q 2025. PARADIGM: A Prospective rAndomized tRial Assessing the safety and effectiveness of
Lake Street initiated coverage of Anteris Technologies Global Corp. with a rating of Buy and set a new price target of $20.00
TD Cowen initiated coverage of Anteris Technologies Global Corp. with a rating of Buy and set a new price target of $15.00
Cantor Fitzgerald initiated coverage of Anteris Technologies Global Corp. with a rating of Overweight and set a new price target of $9.00
8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
3 - Anteris Technologies Global Corp. (0002011514) (Issuer)
3 - Anteris Technologies Global Corp. (0002011514) (Issuer)
4/A - Anteris Technologies Global Corp. (0002011514) (Issuer)
MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o